Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

Representatives of Moderna Biotech UK and NHS England will also be questioned by the inquiry, led by crossbench peer Baroness ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...